LEO Pharma's Commitment to Sustainability
LEO Pharma, a prominent player in dermatological treatments, has boldly announced its goal to achieve net-zero greenhouse gas emissions by 2050. This initiative aligns with global efforts to combat climate change, specifically targeting the commitments outlined in the Paris Agreement. The comprehensive decarbonization plan aims to significantly reduce the company’s carbon footprint and is a crucial step toward protecting our planet for future generations.
Building on Previous Goals
This new pledge builds on LEO Pharma’s previous commitment to slash carbon emissions by over 50% by the year 2030, using 2019 numbers as the starting point. The push for sustainability has become imperative in today's corporate environment, where there is increasing pressure to act responsibly. Christophe Bourdon, the CEO of LEO Pharma, articulated that addressing our planet's climate crisis is fundamental. He emphasized that a sustainable business model is essential for continuing to assist those suffering from skin diseases.
Importance of Corporate Responsibility
Christina Dahl, Head of ESG, DE&I, and Public Affairs at LEO Pharma, underscored the role of corporate responsibility in today's world. She asserted that committing to achieving net-zero emissions is not only an environmental necessity but also a crucial aspect of operating a successful business. With growing climate-related requirements within European supply chains, LEO Pharma acknowledges that their accountability extends beyond the products they offer to patients; it encompasses the operations behind those offerings.
Operational Changes for a Sustainable Future
To ensure success in reaching the set net-zero target by 2050, LEO Pharma intends to bolster its energy-saving initiatives. In 2023, the company took significant steps towards sustainability by enhancing energy efficiency and increasing the usage of renewable energy sources. Notably, it made strides in transitioning towards a more sustainable vehicle fleet, which successfully led to a 39% reduction in Scope 1 and 2 emissions from the 2019 baseline.
Engaging Suppliers in Carbon Reduction
A substantial portion of LEO Pharma's carbon emissions originates from its suppliers and external operations. As highlighted, 83% of their suppliers have either set science-based climate targets or made public commitments to cut CO2 emissions in 2023, marking a pivotal shift towards substantial carbon reduction. However, reaching the ambitious net-zero goal will necessitate deeper collaboration with these suppliers. This collaborative approach will also involve integrating Science-Based Target initiative (SBTi) commitments into their supplier assessment processes, ensuring alignment in efforts to reduce emissions.
A Comprehensive Carbon Reduction Strategy
LEO Pharma plans to create a thorough Carbon Reduction Plan, which will undergo validation by the Science-Based Targets initiative within two years of making the public commitment. As a company dedicated to its purpose, LEO Pharma strives to maximize its positive impact on patients, communities, and the environment. Their focus on minimizing environmental footprints while maintaining transparency and integrity will solidify trust with stakeholders and promote responsible practices.
Commitment from Leadership
The urgency for businesses to embrace sustainability is underscored by the approval of this net-zero commitment from LEO Pharma's Executive Management and Board of Directors. As the company continues to advance its initiatives, it aims not only to comply with environmental regulations but also to establish itself as a leader in sustainable practices within the pharmaceutical industry.
About LEO Pharma
LEO Pharma has a rich history dating back to 1908 and is dedicated to enhancing care for individuals with skin conditions and their families. Majority-owned by the LEO Foundation, the company has focused on dermatological research and development for decades. Currently headquartered in Denmark, LEO Pharma employs a global workforce of approximately 4,000 individuals, serving millions of patients around the globe. In recent assessments, LEO Pharma reported net sales amounting to DKK 11.4 billion in 2023, further establishing its significant role in the dermatology space.
Frequently Asked Questions
What is LEO Pharma's net-zero target?
LEO Pharma aims to achieve net-zero greenhouse gas emissions by 2050 as part of its comprehensive sustainability commitment.
How did LEO Pharma arrive at this goal?
This commitment builds on previous objectives to reduce carbon emissions by over 50% by 2030, using a baseline from 2019.
What strategies will LEO Pharma implement to reach net-zero emissions?
LEO Pharma plans to enhance energy efficiency, use renewable energy, and collaborate with suppliers to reduce overall emissions.
What is LEO Pharma’s approach to supplier emissions?
LEO Pharma will engage suppliers to address their emissions by incorporating their SBTi commitments into the supplier evaluation and selection process.
What is the impact of LEO Pharma's commitment on its operations?
LEO Pharma's move towards sustainability underscores its dedication to responsible business practices and aims to build trust with stakeholders while fulfilling its environmental responsibilities.
